Alivus Life Sciences Ltd (ALIVUS) — share price & stock analysis

Market cap

₹13,948 Cr

P/E

23.9×

ROE

19.0%

vs own history (since 2022)

78th pctile

Book value / share

₹271

EPS (TTM)

₹47.6

10-yr median P/E

20.6×

Revenue (FY26)

₹2,552 Cr

Profit after tax (FY26)

₹564 Cr

Weinstein stage

Stage 2 (12 weeks)

Data as of

1 July 2026

6 of the 6 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 25% — a high-quality engine; effectively no debt; margins near the top of their band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double, and a quarter of the score comes from our earnings-recovery lens (is the profit cycle turning up off its trough?).

Most of this rally is re-rating, not earnings

Since Apr 2022, the stock is up 128% while earnings per share grew 35%. The difference is re-rating — investors paying more for the same rupee of profit.pricettm_eps

That works until it doesn’t: from here, earnings have to do the lifting, because the multiple has already done its part.

Today’s P/E of 23.9× means the market is paying up — this is the expensive end of its own history since 2022 (78th percentile).pe_ratio

Price is the weekly close (₹). EPS is trailing-twelve-month profit per share, anchored on Screener's own snapshots (the window starts at the first stable snapshot — earlier IPO-era share-count revisions are excluded, since they are not earnings events); between snapshots it is filled from price ÷ P/E (an exact identity), and any fill straying more than 18% from the neighbouring snapshots is dropped rather than shown. The lower panel is the P/E — what the market pays per rupee of profit; the dotted line is its long-run median (20.6×).

Stage 2: the trend is up, and has been for 12 weeks

Price trends have a life cycle: they base (1), advance (2), top out (3) and decline (4). This chart is in Stage 2: advancing — 12 weeks so far, confirmed.stage

The price sits above its rising 200-day average (₹997 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

Beating NIFTY 500 for 22 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Up in 8 of 8 years — the long arc of a compounder

Over 8 years, sales went from ₹0.0 Cr to ₹2,552 Cr, and profit from ₹0.0 Cr to ₹564 Cr.revenuenet_profit

Margins widened 35.2 points along the way — growth with improving economics.operating_profit

Sales have gone quiet — growth has stalled

Mar 26 sales were ₹689 Cr, up 6% on the same quarter last year.revenue

That makes 6 quarters of growth in a row — this is a trend, not a blip.revenue

Margins have been rebuilt — 28.7% in FY25 to 31.2% now

Of every ₹100 of sales, the company keeps ₹31.1 as operating profit (a year ago it kept ₹30.6).opm_pct

Zoom out and this is the page's quiet hero: annual operating margin bottomed at 28.7% in FY25 and has been rebuilt to 31.2% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit

Profit grew 15% last quarter

Mar 26 profit after tax was ₹163 Cr, up 15% year on year.net_profit

The profits are real — they turn into cash

Over the last 5 profitable years, the business reported ₹2,407 Cr of profit and collected ₹2,275 Cr of operating cash — about 95% conversion.operating_cash_flownet_profit

When cash tracks profit this closely, the earnings need no asterisk.

The cash cycle is stretching — more money stuck in the pipeline

One rupee now takes about 263 days to go out the door as materials and come back as collected cash — up from 248 days the year before.cash_conversion_cycle

The biggest mover: suppliers being paid sooner (137 → 127 days).payable_days

Building hard — new capacity is under construction

The productive asset base has gone from ₹0.0 Cr (FY18) to ₹1,048 Cr, with another ₹273 Cr of capacity under construction right now.fixed_assetscwip

Work-in-progress is 26% of the existing asset base — that is a serious bet on future demand. Capacity like this shows up in sales with a lag; it is tomorrow’s growth being paid for today.cwip

The build is self-funded: the last 3 years' investing outflow (₹1,302 Cr) fits inside the operating cash the business generated (₹1,371 Cr).investing_cash_flowoperating_cash_flow

Almost no debt — this company cannot be killed by a bad year

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹2 — total borrowings have grown from ₹0.0 Cr to ₹57.0 Cr over the window.borrowings

Every ₹100 kept in the business earns ₹25 — a high-quality engine

Return on capital employed is 25.0% (a year ago: 25.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

Promoter holding dropped in one step — an event, not a slow exit

Promoters hold 74.9% (down 8 points over 8 quarters). Foreign funds own 5.3%, domestic funds 7.3%.promoters_pctfiis_pctdiis_pct

The promoter move came in a single step (Sep 24) — promoters rarely buy on-market, so a jump like this is almost always an allotment, infusion or restructuring: a capital event, not a slow accumulation of conviction. Worth knowing which, before reading it as a signal.promoters_pct

Strong on the data — worth the deeper look if the story keeps its promises

The numbers lean positive, and the price already assumes the good news continues.

Best thing in the data: free cash flow rising (₹−224 Cr → ₹−5.0 Cr).operating_cash_flow

Biggest worry: foreign-fund holding falling (6.6% → 5.3%).fiis_pct

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

Straight answers from the data